Please assess the completion status of the following clinical trial:

Trial Title: Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent symptomatic paroxysmal atrial fibrillation~* Previously failed one or more antiarrhythmic or beta-blocker medication (treatment \> 30 days) or if any contraindications against treatment with these drug.~* Patient is willing and able to attend the scheduled follow-up visits~* Signed informed consent~Exclusion Criteria:~* Persistent or permanent atrial fibrillation~* Previously atrial fibrillation ablation procedure~* Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause~* Severe underlying heart disease (congenital heart disease, significant valvular disease, cardiomyopathy with LVEF \< 35 %, angina pectoris/ ischemic heart disease).~* Severe enlargement of left atrium (\> 45mm)~* Patient with pacemaker~* Failure to obtain informed consent~* Pregnant or breastfeeding women.~* Patient unable to undergo TEE or with documented left atrial thrombus~* Patients with co-morbid conditions who, in the opinion of the investigator, constitute increased risk of general anesthesia or port access, e.g. pleural fibrosis, chronic obstructive pulmonary disease (FEV1 \< 1.5 L/s).~* Known internal carotid artery stenosis (\> 80 %).~* Patients, who are enrolled in another clinical trial~* Life expectancy less than one year~* Previously TIA/stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mini invasive thoracoscopic radiofrequency ablation (Type: ACTIVE_COMPARATOR): Video-assisted thoracoscopic radiofrequency ablation
- Percutaneous ablation (Type: ACTIVE_COMPARATOR): Percutaneous radiofrequency catheter ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).